Journal of Hematology & Oncology · 2025 · 18 citations · 16 references
MedicineOncologyPharmacologyCancer PharmacologyMetastasisSolid Tumor PharmacotherapyBreast Cancer PharmacotherapyMetastatic Breast CancerMetastatic Cancer ManagementMetastatic Disease TreatmentTargeted Cancer TherapyTargeted TherapyAntibody-drug Conjugate AntibodiesAntibody-drug Conjugate TherapyDose Cohort ExpansionMetastatic Breast Cancer TreatmentRefractory Solid TumorsTopoisomerase I InhibitorsTopotecan TherapyTriple-negative Breast Cancer Therapy
BACKGROUND: Sacituzumab tirumotecan (sac-TMT) is an antibody-drug conjugate composed of an anti-TROP2 monoclonal antibody coupled to a cytotoxic belotecan-derived topoisomerase I inhibitor (KL610023) via a novel linker. We report results from the phase 1 dose-escalation cohorts in advanced solid tumors and phase 2 expansion cohorts for metastatic triple-negative breast cancer (TNBC) from the first-in-human MK-2870-001 (KL264-01) study (NCT04152499). METHODS: Patients had unresectable locally advanced/metastatic solid tumors refractory to standard therapies. In the phase 1 dose-escalation cohorts, patients had unresectable locally advanced/metastatic solid tumors refractory to standard therapies. Sac-TMT was administered by intravenous administration every 2 weeks at 2 to 12 mg/kg. In phase 2, patients with TNBC and HR+/HER2- breast cancer received sac-TMT per recommended doses for expansion (RDEs) identified in phase 1. Primary objectives were determining maximum tolerated dose (MTD) of sac-TMT and establishing RDEs (phase 1) and determining ORR per RECIST v1.1 by investigator assessment (phase 2). Adverse events were assessed per NCI-CTCAE version 5.0. RESULTS: Thirty patients were enrolled in phase 1 and received sac-TMT 2 mg/kg (n = 4), 4 mg/kg (n = 7), 5 mg/kg (n = 7), 5.5 mg/kg (n = 5), and 6 mg/kg (n = 7). Five patients had dose-limiting toxicities: grade 3 stomatitis at 4, 5.5, and 6 mg/kg; grade 3 rash at 5 mg/kg; and grade 3 urticaria at 6 mg/kg. MTD was 5.5 mg/kg and RDEs were 4 and 5 mg/kg. In the phase 2 dose expansion, ORR (95% CI) was 34.8% (16.4%, 57.3%) in the 4-mg/kg group (n = 23) and 38.9% (23.1%, 56.5%) in the 5-mg/kg group (n = 36) for TNBC. ORR (95% CI) was 31.7% (18.1%, 48.1%) for HR+/HER2- breast cancer (n = 41). CONCLUSIONS: Sac-TMT demonstrated manageable safety profile in patients with unresectable locally advanced/metastatic solid tumors and promising antitumor activity in metastatic TNBC and HR+/HER2 - breast cancer. Sac-TMT is being investigated in phase 3 studies. TRIAL REGISTRATION: ClinicalTrials.gov, NCT04152499.
16
The National Comprehensive Cancer Network (NCCN).
Elizabeth H. Wood · Europe PMC (PubMed Central) · 2004 · 2.9K citations · Full text
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
Fátima Cardoso, A. Costa, Elżbieta Senkus et al. · Annals of Oncology · 2016 · 2.1K citations · Full text
Medicine, Oncology, Breast Oncology +11
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
Aditya Bardia, Sara A. Hurvitz, Sara M. Tolaney et al. · New England Journal of Medicine · 2021 · 1.5K citations · Full text
Medicine, Oncology, Pharmacology +17
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
Fátima Cardoso, Shani Paluch–Shimon, Elżbieta Senkus et al. · Annals of Oncology · 2020 · 1.4K citations · Full text